Redoxivir Treatment Hope for COVID-19 Severe Patients

Redoxivir Treatment High Hope for COVID-19 Severe Patients

The latest issue of the New England Journal of Medicine published the first batch of clinical results of Redoxivir in the treatment of COVID-19 patients. After 10 days of treatment, 68% of critically ill patients had improved clinical symptoms.

In the early hours of this morning, the latest issue of the New England Journal of Medicine published the first batch of clinical results of Redxivir in the treatment of COVID-19 patients. 

This study included 53 critically ill patients from the United States, Canada, Europe, and Japan. 

Clinicians used Redxivir for treatment based on the principle of sympathetic medication. That is, in the absence of other effective treatments and patients unable to participate in clinical trials, Critically ill patients can make exceptions to the drugs being developed.

Redoxivir treatment accounted for 68% of the treatment, potential hope for the treatment of COVID-19 severe patients

After 10 days of treatment, the clinical symptoms of 36 people (68%) improved, 25 were discharged and 7 died. 

Considering the severity of the symptoms of the patients at the time of treatment, this small-scale cohort study. Although unable to provide clear conclusions, it suggests that the severe patients with Reduxill COVID-19 may have clinical benefits. 

This study also allows us to look forward to the results of the large-scale clinical trial of redoxivir expected to be published at the end of April.

The potential of Ebola drugs

As a nucleoside analog, redoxivir can produce adenosine triphosphate analogs in cells, this substance can inhibit RNA polymerase, thereby inhibiting RNA virus replication. 

Redcive was originally a drug developed by Gilead Sciences for Ebola, but its broad-spectrum antiviral activity makes the drug equally potent against coronavirus. 

Prior to this, ridxivir has shown good prevention and treatment effects in the treatment of MERS patients.

In this COVID-19 epidemic, Ridesivir is also a potential drug, which has been taken into consideration by Chinese and foreign doctors and researchers for a long time. 

As early as January in the treatment of the first new coronavirus patient in the United States, Redcivir was used

After the patient received intravenous injection of redoxivir, the clinical symptoms showed an immediate improvement. 

Although this is only an isolated case, after this, more large-scale clinical trials are rapidly carried out, trying to verify the effect of redoxir through scientific procedures.

On February 3, a clinical trial of redoxivir for the treatment of COVID-19 was launched in many first-line hospitals such as Wuhan Jinyintan Hospital. 

The trial results are expected to be announced at the end of April.

On February 26, Gilead announced that it will be globally.

Two phase III clinical trials were initiated to evaluate the therapeutic effect of redoxivir on patients with severe and moderate clinical symptoms.

Add caption

At the same time, the urgency of the epidemic and the fact that COVID-19 still lacks proven and effective therapies force clinicians to wait until the trial results are announced and the drug is officially marketed. 

Therefore, in clinical practice, doctors in different countries are using antiretroviral drugs, anti-malarial drugs (hydroxychloroquine), plasma of convalescent patients and other sympathetic medication-based therapies, including ridxivir.

68% improved symptoms with redoxivir drug

On January 25, Gilead began accepting applications for sympathetic medications of ridxivir submitted by clinicians to provide drugs for patients whose oxygen saturation does not exceed 94% or who require oxygen support. 

The 53 patients included in this study are eligible critically ill patients. Of these, 30 were undergoing mechanical ventilation, and 4 were undergoing extracorporeal membrane pulmonary oxygenation (ECMO). The condition is more critical.

Of the 53 patients, 40 received a full 10-day treatment, 10 received 5-9 days of treatment, and the remaining 3 received less than 5 days of treatment (due to death or serious adverse reactions). 

After that, the researchers collected the patient's health data on the 28th day.

According to the level of oxygen support, the researchers divided the patient's health from good to bad into the following 6 grades: 

1. discharged from hospital

2. hospitalized without oxygen inhalation

3. hospitalized with oxygen inhalation

4. hospitalized Treatment requires nasal high-flow oxygen therapy or non-invasive mechanical ventilation

5. Hospitalization requires invasive mechanical ventilation or ECMO

6. Death

On the 28th day, if the patient is discharged from the hospital, or if his health has improved by at least 2 levels, it can be defined as clinical improvement.

As a result, of the 53 patients, 36 (68%) had improved clinical symptoms, of which 25 were discharged. 

8 (15%) had worsened health, and 7 of them died. 

After the treatment with redoxir, 17 of the 30 patients who received invasive mechanical ventilation had their cannula removed. 3 of the 4 patients who received ECMO left ECMO.

During the study period, 32 patients had adverse reactions such as elevated liver enzymes, diarrhea, rash, impaired renal function and hypotension. 

Among them, 12 patients had serious adverse reactions, including multiple organ dysfunction syndrome, septic shock, acute kidney injury, and hypotension. 

4 patients discontinued Radecivir treatment due to adverse reactions. 

The adverse reaction of kidney injury has attracted the attention of researchers. 

They pointed out that non-clinical toxicology studies have shown abnormal kidneys, but no clear evidence of renal toxicity caused by redoxivir has been observed.

Cautious hope with co-administration of Redoxivir in the treatment of COVID-19 

It should be pointed out that as the first clinical result of the co-administration of Redoxivir in the treatment of COVID-19 severe patients. 

This study has a small number of patients. Some data is missing, and the observation time is also limited. So it is impossible to draw a direct and clear in conclusion.

But combined with the above data, we still have a glimpse of the potential hope of Redcive. 

Mortality rate in COVID-19 Disease with Ridxivir is Low

According to the study, in case and cohort studies mainly from China, the mortality rate of critically ill patients is 17% to 78%, while the latest study of ridxivir is 13%. 

Considering that the patients in this study were generally more severely symptomatic when receiving treatment, the difference in mortality data suggests that the treatment with ridxivir may have an effect.

In addition, in a clinical study of patients in Wuhan, the mortality rate was 66% among patients who received invasive mechanical ventilation. 

In the latest study, 6 of the 30 patients who received invasive mechanical ventilation died.

Redoxivir may have clinical benefits for COVID-19 severe patients

Therefore, the paper finally pointed out cautiously: The comparison of data with other clinical studies suggests that redoxivir may have clinical benefits for COVID-19 severe patients, but other factors may also lead to differences in results.

Gird Science Chief Medical Officer Merdad Parsey said: 

"The results of this study are encouraging, but the data is limited. 

A number of clinical trials of ridcive are underway and preliminary results are expected to be released in the next few weeks. 

We hope to use more evidence to more comprehensively evaluate the effect of Redcive in COVID-19."

Author's Bio

Name: Gwynneth May

Educational Qualification: MBBS, M.D. (Medicine) Gold Medalist

Profession: Doctor

Experience: 16 Years of Work Experience as a Medical Practitioner

About Me